Because Alk1 expression is also downregulated in glomeruli from biopsies of patients with diabetic nephropathy, these considerations may also apply to human diabetic glomerulopathy, where therapeutic intervention using strategies to modulate BMP signaling may be of therapeutic interest. This evidence concerns the gene ACVRL1 and diabetic kidney disease.